Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020449 · ClinicalTrials.gov registry record · Phase 2
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020449: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00020449 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020449, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill the tumor cells. Combining chemotherapy with interleukin-12 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with interleukin-12 in treating patients who have AIDS-related Kaposi's sarcoma.
Interventions
- DRUG paclitaxel
- DRUG pegylated liposomal doxorubicin hydrochloride
- BIOLOGICAL recombinant interleukin-12
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020449
The ClinicalTrials.gov registry entry for NCT00020449 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00020449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020449 about?
NCT00020449 is a clinical study titled "Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill the tumor cells. Combining chemotherapy with int...
What is the current status of trial NCT00020449?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-01. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00020449?
The interventions under investigation include: paclitaxel (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020449?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.